Since the June 2014 consensus statement published in Post Reproductive Health we have had definitive guidelines on menopause treatment from the National Institute for Clinical Excellence in November 2015. These included robust and evidence based information about many non-estrogen based treatments, which are particularly useful for patients who do not wish to take hormone replacement therapy, or who have medical contraindications to hormonal therapy such as hormone dependent cancers. Whilst none of these therapies is as effective as hormones, we must be able to advise patients about them and recommend which treatments may be helpful for individual women.
WoykaJTannaN. Consensus statement for non-oestrogen based treatment for menopausal symptoms. PRH2014; 20: 76–79.
2.
CummingGCurrieHMorrisE. The need to do better. Are we still letting our patients down and at what cost?Post Reprod Health2015; 21: 56–62.
3.
BarbaMPizzutiLSergiD. Hot flushes in women with breast cancer: state of the art and future perspectives. Expert Rev Anticancer Ther2014; 14: 185–198.
4.
FisherWIJohnsonAKElkinsGR. Risk factors, pathophysiology, and treatment of hot flashes in cancer. CA Cancer J Clin2013; 63: 167–192.
5.
L'EspéranceSFrenetteSDionneA. Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Support Care Cancer2013; 21: 1461–1474.
6.
RadaGCapurroDPantojaT. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev2010; 9: CD004923–CD004923.
7.
LammerinkEAde BockGHSchröderCP. The management of menopausal symptoms in breast cancer survivors: case-based approach. Maturitas2012; 73: 265–268.
8.
SiderasKLoprinziCL. Nonhormonal management of hot flashes for women on risk reduction therapy. J Natl Compr Canc Netw2010; 8: 1171–1179.
9.
National Institute for Clinical Excellence. Family breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164). June 2013, section 1.7.10-1.7.15.
10.
National Institute for Clinical Excellence. Menopause: quality standard, www.nice.org.uk/guidance/qs143 (accessed 10 February 2017).
11.
National Institute for Clinical Excellence. Menopause: clinical guideline – methods, evidence and recommendations (NG23) version 1.5: https://www.nice.org.uk/guidance/ng23/evidence (accessed 12 November 2016).
12.
FreemanGSamuelMLinH. Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol2011; 117: 1095–1104.
13.
AvisNGreendaleG. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med2015; 175: 539–531.
14.
CrumAJLeibiwutzKAVergheseA. Making mindset matter. BMJ2017; 356: J674–J674.
15.
BleaseCRBishopFLKartchukTJ. Informed consent in trials: where is the placebo effect?BMJ2017; 356: j463–j463.
16.
MarsdenJ. The menopause specialist and breast cancer survivorship. PRH2016; 22: 147–154.
17.
SturdeeD. Urogenital atrophy. PRH2014; 20: 73–75.
18.
SassariniJLumsdenMA. Non-hormonal management of vasomotor symptoms. Climacteric2013; 16 (S1): 31–36.
19.
CarrollDGKelleyKW. Use of antidepressants for management of hot flashes. Pharmacotherapy2009; 29: 1357–1374.
20.
VillasecaP. Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: what needs to be known for practice. Climacteric2012; 15: 115–124.
21.
Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause 2015; 22: 1155–1172.
NelsonHVescoKHaneyE. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA2006; 295: 2057–2071.
24.
PandyaKJRaubertasRFFlynnPJ. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flushes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med2000; 132: 788–793.
25.
RadaGCapurroDPantojaT. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev2010; 9: CD004923–CD004923.
26.
OrleansRJLiLKimMJ. FDA approval of paroxetine for menopausal hot flushes. N Engl J Med2014; 370: 1777–1779.
27.
DesmaraisJELooperKJ. Managing menopausal symptoms and depression in tamoxifen users: implications of drug and medicinal interactions. Maturitas2010; 67: 296–308.
28.
Suvanto-LuukkonenEKoivunenRSundstromH. Citalopram and Fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomised, 9 month, placebo controlled, double blind study. Menopause2005; 12: 18–26.
29.
KalayAEDemirBHaberalA. Efficacy of citalopram on climacteric symptoms. Menopause2007; 14: 223–229.
30.
LaCroixAZFreemanEWLarsonJ. Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial. Maturitas2012; 73: 361–368.
31.
EnsrudKEJoffeHGuthrieKA. Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial. Menopause2012; 19: 848–855.
32.
FreemanEWGuthrieKACaanB. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA2011; 305: 267–274.
33.
RamaswamiRVillarrealMDPittaDM. Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat2015; 152: 231–237.
34.
LoprinziCLKuglerJWSloanJA. Venlafaxine in the management of hot flashes in survivors of breast cancer: a randomised, controlled trial. Lancet2000; 356: 2059–2063.
35.
EvamsMLPrittsEVittinghoffE. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomised, controlled trial. Obstet Gynecol2005; 105: 161–166.
36.
SperoffLGassMConstantineG. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomised controlled trail. Obstet Gynecol2008; 111: 77–87.
37.
Hervik JB. Adverse effects of non-hormonal pharmacological interventions in breast cancer survivors suffering from hot flashes. A systematic review and meta-analysis. Breast Cancer Res Treat 2016.
38.
JinYDestaZ. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst2005; 97: 30–39.
39.
LashTLCronin-FentonDAhernTP. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol2010; 49: 305–312.
40.
Huber-wechselbergerAENiedetzkyPAignerI. Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?Wien Med Wochenschr2012; 162: 252–261.
PandyaKJMorrowGRRoscoeJA. Gabapentin for hot flashes in 420 women with breast cancer: a double-blind placebo controlled trial. Lancet2005; 366: 818–824.
43.
LoprinziCLQinRBalcuevaEP. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol2010; 28: 641–647.
44.
LavigneJEHecklerCMathewsJL. A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors. Breast Cancer Res Treat2012; 136: 479–486.
45.
PopATannaNPitkinJ. Breast cancer patient case study – prescribing of gabapentin for vasomotor symptom control and supporting patient compliance/concordance. Maturitas2009; 63: S53–S53.
46.
YamaguchiNOkajimaYFujiiT. The efficacy of nonestrogenic therapy to hot flashes in cancer patients under hormone manipulation therapy: a systematic review and meta-analysis. J Cancer Res Clin Oncol2013; 139: 1701–1707.
47.
WiśniewskaIJochymekBLenart-lipińskaM. The pharmacological and hormonal therapy of hot flushes in breast cancer survivors. Breast Cancer2016; 23: 178–182.
48.
WoykaJ. Alternatives to hormone replacement therapy (HRT) (Sections 1 and 8). Post Reprod Health2016; 22: 67–69.
49.
MaclaughlanDSSalzilloSBoweP. Randomised controlled trial comparing hypnotherapy versus gabapentin for the treatment of hot flashes in breast cancer survivors: a pilot study. BMJ Open2013; 3: e003138–e003138.
GuirguisMAbdelmalakJJusinoE. Stellate Ganglion block for the treatment of hot flashes in patients with breast cancer: a literature review. Ochsner J2015; 15: 162–169.
52.
MaoJJBowmanMAXieSX. Electroacupuncture versus gabapentin for hot flashes among breast cancer survivors: a randomized placebo-controlled trial. J Clin Oncol2015; 33: 3615–3620.
